Vaxcyte Q2 FY26 net loss widens to $284.3 million; R&D expenses climb to $267.9 million - PCVX News | RalliesVaxcyte Q2 FY26 net loss widens to $284.3 million; R&D expenses climb to $267.9 million
P
PCVX• VAX-31 Phase 3 timeline
- VAX-31 adult Phase 3 OPUS trials are fully enrolled.
- OPUS-1 topline safety, tolerability and immunogenicity data are expected in Q4 2026.
- OPUS-2 and OPUS-3 results are expected in H1 2027, supporting a planned BLA submission and potential U.S. commercial launch.
Quarterly results and spending increase
- Vaxcyte posted a Q2 net loss of $284.3 million, widening from $166.6 million a year earlier.
- R&D expense climbed to $267.9 million from $194.2 million on higher PCV development and manufacturing costs, plus OPUS Phase 3 trial spending.
- Cash, cash equivalents and investments rose to $2.51 billion as of June 30, 2026, from $2.44 billion at year-end.
MUR
•
